Deep Dive on the Aurora + RTPY SPAC Deal w/ Chris Urmson and Michael Thompson

by | Oct 12, 2021

Aurora CEO Chris Urmson and Reinvent’s (RTPY) Michael Thompson join David Drapkin to talk self-driving technology, why Aurora is setup for success, and the overall SPAC market.

Aurora / Reinvent just announced their shareholder vote on the deal is happening on November 2nd.

Reinvent Technology Partners Y (RTPY), is a special purpose acquisition company (SPAC) led by LinkedIn co-founder Reid Hoffman and Zynga founder Mark Pincus.

More on Aurora: https://aurora.tech/
More on Reinvent: https://www.reinventtechnologypartners.com/

Discussion Details

  • Overview of Aurora and its technology, partnerships
  • Why public now vs. an additional private round
  • Why Reinvent, process of finding a SPAC
  • Sponsor alignment with public shareholders
  • Keys to success as a public company
  • 2023 Truck launch and go-to-market strategy
  • Why Aurora vs. a GM or Waymo?
  • Valuation in context vs. Peers and latest raise?
  • Telling Aurora’s story to the public
  • Capital structure of the company post close
  • Reinvent as a SPAC sponsor – picking SPAC targets
  • Future of the SPAC market from a sponsor perspective
  • Biggest Risk for Aurora
<a href="https://www.boardroomalpha.com/author/draps/" target="_self">David Drapkin</a>

David Drapkin

Spent his formative years at Goldman Sachs and now embraces the start-up life in NYC. A long suffering Oakland (Las Vegas) Raiders fan and graduate of the Wharton School at the University of Pennsylvania. Semi-professional go-kart racer waiting for his shot.

Know Who Drives Return

Objective, data-driven assessments for every public company director and officer.

SPAC Analytics & Database

Comprehensive research and analytics on every SPAC, sponsor, and deal. Real-time alerts, yields, red flags, filings, investors, and much more. API access to institutional grade SPAC database.

Monthly SPAC Review

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

SPAC Research & Analysis

SPAC IPO for Aimfinity

An IPO and another metaverse play. Elon buying TWTR is a good time for a DWAC and CFVI status check. And the rest of the day’s news in SPACs.

Two SPAC Deals to Start the Week

Monday’s buzzing with two med-related SPAC deals. Convert and PIPE action. And the rest of the day’s news in SPACs.

DA for LMAO and SeaStar Medical

Ending the week with a deal announcement for LMAO and SeaStar Medical. And the rest of the day’s news in SPACs.

Boardroom Alpha Daily Read

We take a closer look at fundamentals at baby and children’s apparel retailer Carter’s (CRI) on the heels of the company’s ESG announcement.

Know Who Drives Return Podcast

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.